16 September 2025 | News
Image Courtesy: Public Domain
Conceivable Life Sciences announced its $50 million Series A funding round to accelerate the development and commercialization of the world's first AI-powered, automated IVF lab. The funding will support the company's mission to make this Nobel Prize-winning therapy more accessible, scalable, and effective, delivering improved pregnancy outcomes.
The Series A round was led by Advance Venture Partners (AVP) with participation from existing investors ARTIS Ventures, Stride, and ACME . This round brings Conceivable's total funding to $70 million, including its $20 million seed round, which closed in December 2022. This cements Conceivable's position as the most highly funded biotech startup in Latin America.
“This investment is a milestone, not only for Conceivable, but for the entire Mexican biotechnology industry. While this specific funding round is led by international firms, it is a powerful signal to Mexican investors about the immense potential here at home. Their participation would not only be an investment in a global leader, but a direct commitment to strengthening a company with deep ties to Mexico,” commented Dr. Alejandro Chávez-Badiola, reproductive endocrinologist, co-founder and medical director of Conceivable Life Sciences, and founder of Hope IVF Mexico.
The transformation of IVF through AI and automation
For decades, IVF laboratories have relied on manual, artisanal processes that represent enormous variability and lead to inconsistent results for infertile patients. At its core, IVF involves performing procedures at the cellular level and under a microscope, in which eggs and sperm are manipulated to create a blastocyst (fertilized egg). Traditionally, this critical work is largely performed with human hands and eyes, leaving critical procedures vulnerable to various variables.
Conceivable is revolutionizing IVF through its proprietary automated IVF lab system, AURA . This technology aims to bring robotic precision and AI algorithmic accuracy to eliminate variability and standardize the 200+ steps required for the process, potentially delivering consistently successful IVF outcomes.
"This funding reinforces our vision of transforming IVF through AI-powered robotic automation," said Alan Murray , Co-Founder and CEO of Conceivable. "Our platform addresses the core challenges facing fertility clinics today: unpredictable success rates, capacity constraints, and accessibility barriers. This investment allows us to accelerate the commercialization of this groundbreaking technology."
Conceivable is in active clinical operations and is currently conducting a pilot study of AURA in Mexico City with 100 patients. “The ongoing pregnancy outcomes from the current trial are quite positive, and in the proof of concept prior to the current protocol, 18 babies were born with prototype instruments,” said Dr. Alejandro Chávez-Badiola, reproductive endocrinologist, co-founder and chief medical officer of Conceivable Life Sciences, and founder of Hope IVF Mexico. “Early indications of clinical key performance indicators (KPIs) are very promising and demonstrate that robotic precision and AI-driven protocols will outperform traditional manual approaches.”
Strategic use of capital
The Series A funding will support Conceivable Life Sciences' U.S. debut next year, expanding its partnerships with fertility networks in 2026, marking the U.S. commercial launch of the world's first automated IVF lab. The investment will also support AURA's commercial expansion in Mexico.
Addressing critical needs of the fertility industry
The global fertility market faces significant challenges, including growing demand (experts estimate that unmet demand for IVF is 10 times higher than current figures), limited clinic capacity, and cost barriers that impact accessibility. Conceivable addresses key laboratory challenges by increasing efficiency, bringing consistency to workflows, improving success rates, and reducing costs for patients.
“The fertility industry is at a critical inflection point where innovation will dramatically revolutionize access to this treatment,” said Alex Christ , General Partner at Advance Venture Partners. “We saw a fragmented landscape of companies building low-impact, point solutions for individual IVF processes, but only Conceivable addressed the complete end-to-end approach to IVF that truly propels the industry forward. Conceivable’s technology will enable the entire industry to deliver more consistent, scalable, and, most importantly, affordable fertility care to the families who need it most.”
